Ofichem Group

What Ofichem Group does

Ofichem Group is a family-owned European contract development and manufacturing organization (CDMO) and pharmaceutical supplier founded in 1975 in the Netherlands by Dr. Otto H. Oldenziel. As of 2026, the group operates through unified branding across six legal entities spanning the Netherlands (Laboratorium Ofichem BV, Ofichem BV, Ofipharma BV, Ofimedicine BV, Avivia BV), Sweden (Ofichem Uppsala AB), and Germany (minority-held Incopharm GmbH), with a regional sourcing office in Hangzhou, China and a US registration office in Winston-Salem, North Carolina. Leadership transferred from the founder to his son Dr. Weite H. Oldenziel in 2006, who remains CEO and owner; the company has never raised external private equity or venture capital.

The business is organized around three integrated service pillars. Drug Substance Services cover API development from preclinical medicinal chemistry through GMP manufacturing, with 15 workshops ranging from 20L to 2x 2000L reactors and commercial production of approximately 50 APIs under EU-GMP/FDA approval. Drug Product Services span formulation development, clinical trial material supply, oral solid dose manufacturing at the Leiden facility (1.5 billion tablets per year capacity, 4 high-speed blister lines, 1 bottle line, TraceLink serialization), and analytical services including dissolution testing, reverse engineering (deformulation), and excipient characterization. Sourcing and Distribution provides a global catalog of 400+ third-party APIs from stock, plus repackaging services for compounding pharmacies and hospitals. Analytical capabilities extend to emerging modalities such as proteins, peptides, antibodies, bioconjugates, oligonucleotides, and PROTACs.

Ofichem serves pharmaceutical and biotech companies (from early-phase biotech through commercial generics), compounding pharmacies and hospitals, and veterinary pharmaceutical manufacturers across Europe, North America, and Asia. Revenue is generated primarily through B2B professional services contracts (CDMO development and manufacturing) and transactional API distribution and repackaging. Pricing is quote-based and not publicly disclosed. The go-to-market relies on enterprise field sales, direct scientist engagement, industry conferences (e.g., CDMO Live Europe 2026), a content-led website, and an Ofipharma webshop for compounding pharmacy customers. Recent strategic activity centers on inorganic capability expansion: the 2023 acquisition of InnoGenerics (Leiden drug product site), the July 2025 acquisitions of Avivia (Nijmegen formulation development) and the Meribel/OT Chemistry Uppsala site (preclinical drug substance), followed by the April 2026 brand unification under a single Ofichem identity.

Name

Ofichem Group

Legal name

Laboratorium Ofichem B.V.

Website

https://ofichem.com

Company type

Private

Founded year

1975

Operating status

Operating

Headcount range

51–100 employees

Short description

Ofichem Group is a family-owned European CDMO and pharmaceutical supplier founded in 1975, offering integrated drug substance development, drug product manufacturing, and API sourcing and distribution to pharmaceutical, biotech, compounding pharmacy, and veterinary customers across Europe, North America, and Asia.

Ownership category

akta.pro rank

Product category

Pharmaceutical CDMO Services

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (42421), Packaging and Labeling Services (56191)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

akta.pro secondary industries

Small-Molecule API & Intermediates CDMO (HLAGABAA), Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), Packaging, Labeling & Serialization (Clinical/Commercial) CDMO (HLAGABAJ), Small-Molecule API Commercial Manufacturing (HLAGAHAB)

Keywords

• Pharmaceutical CDMO services
• Active pharmaceutical ingredients
• API manufacturing
• Oral solid dose manufacturing
• Drug product formulation

Headquarters

HQ city

Ter Apel

HQ country

Netherlands

HQ region

Europe

Offices7 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Operations, Personnel, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. Drug Substance CDMO Services: API and drug substance development and GMP manufacturing services including synthetic route scouting, process development, analytical method development, and scale-up production from preclinical to commercial scale
2. Drug Product Manufacturing: European drug product manufacturing for clinical supply to commercial scale, including tableting, film coating, and packaging services with capacity of 1.5 billion tablets per year
3. API Sourcing and Distribution: Supply of high-quality APIs from own production and third-party suppliers with stock availability, supporting registration processes and supply chain security. Commercially delivers over 400 APIs from third-party suppliers and approximately 50 APIs in-house
4. Repackaging Services: GMP-compliant repackaging of APIs into custom volumes for compounding pharmacies, hospitals, and industry partners

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Core offering

Ofichem Group is a family-owned Contract Development and Manufacturing Organization (CDMO) that provides integrated end-to-end pharmaceutical services across drug substance (API development and GMP manufacturing), drug product (formulation development, clinical trial material supply, commercial oral solid dose manufacturing, and packaging), and global API sourcing and distribution. The company commercially produces approximately 50 APIs in-house under EU-GMP and FDA approval, distributes over 400 third-party APIs from stock, and operates five European manufacturing and development sites.

Product overview

Ofichem Group is a family-owned CDMO (Contract Development and Manufacturing Organization) and pharmaceutical supplier offering an integrated portfolio spanning three core service pillars: Drug Substance Services (development and GMP manufacturing of APIs), Drug Product Services (formulation development, clinical trial material supply, commercial oral solid dose manufacturing, and packaging), and Sourcing & Distribution (global API sourcing, repacking, and supply chain services). The portfolio is unified under the Ofichem umbrella following the consolidation of multiple brands (Ofichem BV, Ofipharma BV, Ofimedicine BV, Laboratorium Ofichem BV, Ofichem Uppsala AB, and Avivia BV). Key acquired capabilities include Avivia B.V. (formulation development), InnoGenerics/Leiden (drug product manufacturing as Ofimedicine), and Uppsala site (early-phase non-GMP drug substance development). The company commercially produces approximately 50 APIs and sources over 400 APIs, serving both human and veterinary pharmaceutical markets.

Differentiator

Problem solved

Functional benefit

Products and services

• Drug Substance Services Comprehensive API and drug substance development and manufacturing services spanning synthetic route scouting, medicinal chemistry, process development, analytical method development, scale-up, and GMP production from grams to multi-kilogram batches for pharmaceutical and biotech clients.
• Drug Product Services End-to-end drug product development and manufacturing services including formulation development, clinical trial material supply, commercial tablet manufacturing, packaging, and analytical services for oral solid dosage forms targeting pharmaceutical innovators and generic manufacturers.
• Drug Substance Development Preclinical medicinal chemistry, process development, and regulatory support from discovery to scale-up for diverse drug modalities including small molecules, controlled substances, oligonucleotides, PROTACs, and bioconjugates (ADCs).
• Drug Substance & API Manufacturing Services GMP manufacturing of APIs from early clinical to commercial scale, with reactor capabilities ranging from 20L to 2000L across 15 workshops, supporting ASMF/DMF submissions worldwide under EU-GMP and FDA approval.
• Catalog API Portfolio of approximately 50 commercially produced APIs manufactured in the Netherlands under EU-GMP and FDA approval, available with CTD-ASMF and/or CEP documentation.
• Drug Substance Analytical Services Physical and chemical analyses of pharmaceutical raw materials and drug substances, including method development, validation, impurity profiling, nitrosamine testing, and bioanalytical services in compliance with GMP, ICH and ISO standards.
• Drug Product Development Comprehensive formulation development services ranging from complex formulation development, reverse engineering, advanced analytics, to scalable manufacturing process design covering multiple dosage forms (tablets, capsules, powders, injections, gels) and technologies (controlled release, taste masking, micro-encapsulation).
• Clinical Trial Material Supply Manufacturing of clinical trial materials in tablet, powder, and granulate forms for Phase 2 and Phase 3 studies with efficient transition to commercial scale for pharmaceutical innovators.
• Drug Product Manufacturing European oral solid dose manufacturing with annual capacity of 1.5 billion tablets, featuring high shear wet granulation, direct compression, film coating, and sugar coating capabilities targeting generic and innovative pharmaceutical clients.
• Drug Product Packaging Primary and secondary drug product packaging with annual capacity of 1 billion tablets in bottles and 1.5 billion in blisters, featuring 4 high-speed blister lines, 1 bottle line, and TraceLink serialization meeting regulatory track-and-trace requirements.
• Drug Product Analytical Services Comprehensive analytical services for drug products including method development, validation, dissolution testing (USP I-IV), excipient analysis, reverse engineering, and stability studies.
• Pharmaceutical Reverse Engineering Services Deformulation and reverse engineering of pharmaceutical formulations, providing Q1/Q2 (qualitative/quantitative composition) insights and Q3 (physical equivalence) characterization to support generic development, competitive analysis, and patent evaluation.
• Excipient Analysis & Characterization Quantitative excipient profiling and characterization services supporting generic development, comparability, and troubleshooting for formulation composition and functional roles.
• API Sourcing and Distribution Global API sourcing from leading producers worldwide with over 400 APIs from third-party suppliers available from stock, complemented by registration-ready documentation support for pharmaceutical and veterinary customers.
• Repacking Services GMP-grade repackaging of APIs into custom volumes for compounding pharmacies, hospitals, and industry partners, ensuring compliance with EU regulations and pharmacopoeia standards.
• Sourcing and Distribution Analytical Services Analytical testing services integrated into sourcing and distribution operations, ensuring compliance and quality verification of pharmaceutical ingredients with support for small molecules and complex large molecules including proteins, peptides, antibodies, and oligonucleotides.

Quantifiable outcome

• 50+ years of regulatory expertise since 1975
• +2 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature4 records

Partnerships

Three partnerships are on record, tiered core.

• Meribel Pharma SolutionscoreOthers · 29 July 2025Acquisition of Meribel Pharma Solutions' Uppsala site in Sweden, formerly part of Recipharm and known as OT Chemistry. The site specializes in small-scale, early-phase development work with expertise spanning traditional small molecule and emerging modalities such as ADCs, oligonucleotides and PROTACs. Home to 20 employees and providing access to a portfolio of more than 40 biotech and mid-sized pharma clients.
• Avivia B.V.coreOthers · 9 July 2025Acquisition of Avivia B.V., a formulation development specialist based in Nijmegen, Netherlands. The deal enhances Ofichem's capacity to support complex formulation challenges from early development to GMP manufacturing. Avivia brings over 25 years' experience and a team of 10 specialized professionals in formulation development, analytical method development, dissolution testing, and excipient characterization.
• Rephine LtdcoreStrategic or Co-development Partner · 16 May 2022Strategic pharmaceutical audit partnership where Rephine assumes responsibility for Ofidit's third-party audit service for customers, while Ofidit's audit reports are featured in Rephine's extensive audit library - the largest repository of live pharmaceutical GMP audits globally. The partnership enables Ofidit to offer and develop a broader portfolio of services in response to rapidly-changing pharmaceutical industry requirements.

Scale indicators9 records

Recent moves10 records

Expansion highlights6 records

Direct peers

• Recipharm: Recipharm is a Europe-headquartered CDMO offering drug substance and drug product services, including oral solid dose manufacturing — the closest direct peer to Ofichem's integrated small-molecule CDMO offering and the seller of the Uppsala site Ofichem acquired.
• Siegfried Holding: Siegfried is a Swiss-listed CDMO with API manufacturing plus oral and sterile drug product services, overlapping directly with Ofichem's drug substance-to-drug product integrated platform and competing for the same mid-pharma and biotech customers in Europe.
• Carbogen Amcis (Dishman Carbogen Amcis): Carbogen Amcis is a Swiss-based CDMO specializing in API process development, GMP manufacturing and highly potent APIs — directly comparable to Ofichem's drug substance CDMO services including its work on ADCs and other complex modalities.
• CordenPharma: CordenPharma is a full-service CDMO offering API, drug product (including oral solid dose) and packaging services from European facilities — directly comparable to Ofichem's integrated CDMO offering and competing for similar generic and specialty pharma customers.
• Eurofins CDMO (Eurofins PSS Insourcing Solutions): Eurofins CDMO services provide contract development and manufacturing including API and drug product services across European sites — comparable to Ofichem in pharma CDMO and analytical services, and operates at a similar European mid-sized scale.
• PharmaZell (formerly known as part of the European API landscape): PharmaZell is a European-headquartered API manufacturer focused on specialty and generic APIs — closely comparable to Ofichem's catalog-API and small-molecule drug substance manufacturing business, competing in the same niche mid-pharma segment.

Broad incumbents

• Lonza Group: Lonza is the world's largest CDMO with broad small-molecule API, biologics and drug product capabilities — a broad incumbent against which Ofichem competes on integrated CDMO bids, but operates at vastly greater scale across multiple modalities.
• Catalent: Catalent is a global CDMO with strong oral solid dose and softgel drug product capabilities — a broad incumbent competitor in the same end-markets as Ofichem's Leiden drug product operations, though with much larger capacity and broader modality coverage.
• Piramal Pharma Solutions: Piramal Pharma Solutions offers integrated API and drug product CDMO services globally, including ADC and complex molecule capabilities — overlapping with Ofichem's emerging-modality and integrated CDMO positioning but at significantly larger scale.

Emerging players

• ChemPartner: ChemPartner is a China-based contract research and API development/manufacturing organization — comparable to Ofichem in providing discovery-to-GMP drug substance services, and relevant as both a partner in the Asian sourcing network and a competitor for early-phase biotech programs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/ofidit
• Xx.com/OfichemGroup

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ofichem Group